Quick Answer
Beam Therapeutics Inc. reported Operating Income Loss of -$383.69 million for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +7.7% in Operating Income Loss from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Operating Income Loss has declined by 410.5%.
- Historical annual values: Fiscal year 2025: -$383.69 million | Fiscal year 2024: -$415.57 million | Fiscal year 2023: -$176.49 million | Fiscal year 2022: -$338.48 million | Fiscal year 2021: -$392.47 million | Fiscal year 2020: -$132.76 million | Fiscal year 2019: -$75.15 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: